The role of candesartan or carvedilol for prevention of anthracycline induced subclinical cardiotoxicity in breast cancer patients.

Back

HFA Premium Access

The role of candesartan or carvedilol for prevention of anthracycline induced subclinical cardiotoxicity in breast cancer patients.

Session: Rapid Fire 4 - Chronic heart failure - Pharmacology

Topic: Cardiotoxicity of Drugs and Other Therapies

Speaker: Doctor M. Lee (Daejeon, KR)

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Doctor Myunhee Lee

Daejeon St. Mary's Hospital, Daejeon (Korea (Republic of))

0 follower

14 more presentations in this session

Heart failure outcomes in patients with diabetes with and without atrial fibrillation - data from the EMPA-REG OUTCOME study

Speaker: Professor M. Boehm (Homburg, DE)

Eligibility for EMPEROR trials in a real-world heart failure population: data from the Swedish heart failure registry

Speaker: Doctor T. Thorvaldsen (Stockholm, SE)

Metformin reduces myocardial oxygen consumption and improves myocardial efficiency in pre-diabetic heart failure patients

Speaker: Doctor A. Larsen (Herning, DK)

Effects of combined uptitration of ACE-inhibitors and beta-blockers in heart failure with reduced ejection fraction

Speaker: Doctor W. Ouwerkerk (Amsterdam, NL)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in heart failure patients with mid-range and preserved ejection fraction and clinical outcomes: from the KCHF Registry

Speaker: Doctor Y. Yoshikawa (Kyoto, JP)

Access the full session

Rapid Fire 4 - Chronic heart failure - Pharmacology

Speakers: Doctor M. Lee, Professor M. Boehm, Doctor T. Thorvaldsen, Doctor A. Larsen, Doctor W. Ouwerkerk...

Access

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources